Clinical trial
Afatinib Expanded Access Program
NCT01649284
Study timeline
Study start (unknown)2012-07-01Date precision: month
Registry last updated2016-11-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
afatinibDRUG
Sponsors & collaborators
Boehringer Ingelheimlead sponsor
Mapped research locations
New YorkNew York, United States2JacksonvilleFlorida, United States2HollywoodFlorida, United States2PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1SeattleWashington, United States1ColumbusOhio, United States1PortlandOregon, United States1OrlandoFlorida, United States1DetroitMichigan, United States1OmahaNebraska, United States1Ann ArborMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01649284 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.